Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/8/2007
 
First Published:
8/24/2003
1.
Phase III Randomized Study of Monoclonal Antibody B43.13 in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0211008
UNITHER-OVA-Gy-17(A), NCT00050375
Last Modified:
5/31/2007
 
First Published:
1/1/1999
2.
Phase IIB Randomized Study of OvaRex Monoclonal Antibody B43.13 as Post Chemotherapy Consolidation in Patients With Stage III or IV Ovarian Epithelial, Tubal, or Peritoneal Adenocarcinoma (Summary Last Modified 04/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
ALTAREX-OVA-Gy-07
ALTAREX-961452, ALTAREX-OVA-Gy-06, NCI-V98-1488, NCT00003634
Last Modified:
6/1/2007
 
First Published:
10/1/1999
3.
Phase II Randomized Study of OvaRex Monoclonal Antibody B43.13 in Patients with Epithelial Adenocarcinoma of the Ovary, Fallopian Tube, or Peritoneum and Elevated Serum CA 125, But Without Other Evidence of Disease (Summary Last Modified 07/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
ALTAREX-OVA-Gy-10
OU-08111, NCT00004064
Last Modified:
12/12/2007
 
First Published:
10/23/2007
4.
Randomized Pilot Study of Consolidation Therapy Comprising Adjuvant Oregovomab With Versus Without Cyclophosphamide in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Adenocarcinoma That Responded to Second-Line Taxane/Platinum-Based Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Biomarker/Laboratory analysis, Treatment
Temporarily closed
18 and over
NCI
GOG-0243
GOG-0243, NCT00551265
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute